TP53 and progression from Barrett’s metaplasia to oesophageal adenocarcinoma in a UK population cohort

Background and aims: Oesophageal adenocarcinoma frequently develops on a background of metaplastic Barrett’s epithelium. The development of malignancy is accompanied by genetic alterations, which may be promising biomarkers of disease progression. Methods: A case control study was conducted nested within a large unselected population based cohort of Barrett’s patients. Incident oesophageal malignancies and high grade dysplasias were identified. For each case up to five controls were matched on age, sex, and year of diagnosis. Biopsies from the time of diagnosis of Barrett’s epithelium were stained immunohistochemically for TP53, cyclin D1, cyclooxygenase 2 (COX-2), and β-catenin proteins. Results: Twenty nine incident oesophageal malignancies and six cases of high grade dysplasia were identified. The odds of diffuse or intense TP53 staining were substantially elevated in biopsies from patients who developed oesophageal adenocarcinoma compared with controls (odds ratio (OR) 11.7 (95% confidence interval (CI) 1.93, 71.4)). This difference was also present when all cases were considered (OR 8.42 (95% CI 2.37, 30.0). Despite the association with TP53 staining, only 32.4% of cases had an initial biopsy showing diffuse/intense TP53 staining. There were no significant associations between cyclin D1, COX-2, or β-catenin staining and case control status. The OR for positive staining for both TP53 and COX-2 was markedly increased in cases compared with controls (OR 27.3 (95% CI 2.89, 257.0)) although only 15% of cases had positive staining for both markers. Conclusions: Immunohistochemical detection of TP53 expression is a biomarker of malignant progression in Barrett’s oesophagus but sensitivity is too low to act as a criterion to inform endoscopic surveillance strategies. Additional biomarkers are required which when combined with TP53 will identify, with adequate sensitivity and specificity, Barrett’s patients who are at risk of developing cancer.

[1]  C. Wild,et al.  Risk Factors, DNA Damage, and Disease Progression in Barrett's Esophagus , 2005, Cancer Epidemiology Biomarkers & Prevention.

[2]  D. Lane,et al.  P53 abnormalities and outcomes in colorectal cancer: a systematic review , 2005, British Journal of Cancer.

[3]  Patricia L. Blount,et al.  The Combination of Genetic Instability and Clonal Expansion Predicts Progression to Esophageal Adenocarcinoma , 2004, Cancer Research.

[4]  D. Meek,et al.  The p53 response to DNA damage. , 2004, DNA repair.

[5]  J. Prolla,et al.  p53 protein overexpression and p53 mutation analysis in patients with intestinal metaplasia of the cardia and Barrett's esophagus. , 2004, Cancer letters.

[6]  L. Lovat,et al.  Gastrin-Induced Cyclooxygenase-2 Expression in Barrett’s Carcinogenesis , 2004, Clinical Cancer Research.

[7]  S. Meltzer,et al.  Biomarkers of Esophageal Adenocarcinoma and Barrett’s Esophagus , 2004, Cancer Research.

[8]  A. Gavin,et al.  Risk of adenocarcinoma in Barrett's oesophagus: population based study , 2003, BMJ : British Medical Journal.

[9]  Christopher P. Wild,et al.  Reflux, Barrett's oesophagus and adenocarcinoma: burning questions , 2003, Nature Reviews Cancer.

[10]  R. Cestari,et al.  Long-term endoscopic surveillance of patients with Barrett's esophagus. incidence of dysplasia and adenocarcinoma: a prospective study , 2003, American Journal of Gastroenterology.

[11]  A. Gavin,et al.  Mortality in Barrett’s oesophagus: results from a population based study , 2003, Gut.

[12]  A. Polednak,et al.  Trends in survival for both histologic types of esophageal cancer in U.S. surveillance, epidemiology and end results areas , 2003, International journal of cancer.

[13]  R. Playford,et al.  Current practice in surveillance strategy for patients with Barrett's oesophagus in the UK , 2003, Alimentary pharmacology & therapeutics.

[14]  D. Vidaud,et al.  Cyclooxygenase‐2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma , 2003, Histopathology.

[15]  I. Johnson,et al.  Cyclo‐oxygenase‐2 expression in Barrett's oesophageal carcinogenesis: an immunohistochemical study , 2003, Alimentary pharmacology & therapeutics.

[16]  S. Spechler,et al.  Hallmarks of cancer progression in Barrett's oesophagus , 2002, The Lancet.

[17]  J. Goldblum,et al.  p53 expression in low grade dysplasia in Barrett's esophagus: correlation with interobserver agreement and disease progression , 2002, American Journal of Gastroenterology.

[18]  H. Barr,et al.  Endoscopic surveillance of patients with Barrett’s oesophagus , 2002, Gut.

[19]  G. Jenkins,et al.  Genetic pathways involved in the progression of Barrett's metaplasia to adenocarcinoma , 2002, The British journal of surgery.

[20]  P. Dickman,et al.  Improved survival in both histologic types of oesophageal cancer in Sweden , 2002, International journal of cancer.

[21]  J. Goldblum,et al.  Acid suppression therapy may not alter malignant progression in Barrett's metaplasia showing p53 protein accumulation , 2002, American Journal of Gastroenterology.

[22]  David Sidransky,et al.  Emerging molecular markers of cancer , 2002, Nature Reviews Cancer.

[23]  Noel S Weiss,et al.  Surveillance and survival in Barrett's adenocarcinomas: a population-based study. , 2002, Gastroenterology.

[24]  G. A. Meijer,et al.  Surveillance in Barrett's Oesophagus: a Critical Reappraisal , 2002, Scandinavian journal of gastroenterology. Supplement.

[25]  P. Blount,et al.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. , 2001 .

[26]  M S Pepe,et al.  Phases of biomarker development for early detection of cancer. , 2001, Journal of the National Cancer Institute.

[27]  Prateek Sharma,et al.  p53 protein overexpression in low grade dysplasia (LGD) in barrett's esophagus: Immunohistochemical marker predictive of progression , 2001, American Journal of Gastroenterology.

[28]  F. Bosman,et al.  p53 Gene Mutation and Protein Accumulation during Neoplastic Progression in Barrett's Esophagus , 2001, Modern Pathology.

[29]  R. DuBois,et al.  Cyclooxygenase-2 Expression in Barrett's Esophagus , 2001, Digestive Diseases and Sciences.

[30]  S. Attwood,et al.  Cyclooxygenase-2 expression in the Barrett's metaplasia–dysplasia–adenocarcinoma sequence , 2001, American Journal of Gastroenterology.

[31]  R. Playford,et al.  Final results from 10 year cohort of patients undergoing surveillance for Barrett's oesophagus: observational study , 2000, BMJ : British Medical Journal.

[32]  S. Groshen,et al.  Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[33]  F. Bosman,et al.  Nuclear accumulation of beta-catenin is a common and early event during neoplastic progression of Barrett esophagus. , 2000, American journal of clinical pathology.

[34]  D. Forman,et al.  Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. , 2000, Journal of the National Cancer Institute.

[35]  G. Lapertosa,et al.  Long-term endoscopic surveillance of patients with Barrett's esophagus. A prospective study , 2000 .

[36]  M. Omary,et al.  Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. , 2000, Gastroenterology.

[37]  J. Bartelsman,et al.  Surveillance of Barrett's oesophagus: physicians' practices and review of current guidelines , 2000, European journal of gastroenterology & hepatology.

[38]  N. Powe,et al.  Management of Barrett's esophagus: a national study of practice patterns and their cost implications , 1999, American Journal of Gastroenterology.

[39]  B. Reid,et al.  p53-mutant clones and field effects in Barrett's esophagus. , 1999, Cancer research.

[40]  M. Younes,et al.  p53 Protein Accumulation Is a Specific Marker of Malignant Potential in Barrett's Metaplasia , 1997, Digestive Diseases and Sciences.

[41]  G. Viale,et al.  p53 protein accumulation and p53 gene mutation in esophageal carcinoma , 1997, Cancer.

[42]  G. Thomas,et al.  TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. , 1994, Gastroenterology.

[43]  C. Harris,et al.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.

[44]  J B Wong,et al.  A guide for surveillance of patients with Barrett's esophagus. , 1994, The American journal of gastroenterology.

[45]  D. Beer,et al.  Intestinal differentiation and p53 gene alterations in barrett's esophagus and esophageal adenocarcinoma , 1994, International journal of cancer.

[46]  F. Ellis,et al.  Endoscopic surveillance of Barrett's esophagus. Does it help? , 1993, The Journal of thoracic and cardiovascular surgery.

[47]  F. Duhaylongsod,et al.  Barrett's esophagus and adenocarcinoma of the esophagus and gastroesophageal junction. , 1991, The Journal of thoracic and cardiovascular surgery.

[48]  Carissa A. Sanchez,et al.  Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression , 2001, American Journal of Gastroenterology.

[49]  T Mach,et al.  [Barrett's metaplasia]. , 1999, Folia medica Cracoviensia.

[50]  Dawn Provenzale,et al.  Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk , 1999, American Journal of Gastroenterology.

[51]  P. Maxwell,et al.  Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia. , 1998, British Journal of Cancer.

[52]  H. Barr,et al.  Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. , 1998, The American journal of pathology.